Neurology

ANI Pharmaceuticals Announces Presentation of New Preclinical DataANI Pharmaceuticals Announces Presentation of New Preclinical Data

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance…

2 weeks ago
ANI Pharmaceuticals Announces Presentation of New Preclinical DataANI Pharmaceuticals Announces Presentation of New Preclinical Data

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance…

2 weeks ago
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual MeetingPositive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting

Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting

-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people…

2 weeks ago
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual MeetingPositive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting

Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting

-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people…

2 weeks ago
Huntsville Memorial Hospital Reduces Patient Transfers and Enhances Local Care with Onsite EEG Program Powered by ZetoHuntsville Memorial Hospital Reduces Patient Transfers and Enhances Local Care with Onsite EEG Program Powered by Zeto

Huntsville Memorial Hospital Reduces Patient Transfers and Enhances Local Care with Onsite EEG Program Powered by Zeto

HUNTSVILLE, Texas, June 11, 2025 /PRNewswire/ -- Zeto, Inc. is proud to announce the success of a new onsite EEG…

2 weeks ago
uniQure Announces Appointment of Kylie O’Keefe  as Chief Customer and Strategy OfficeruniQure Announces Appointment of Kylie O’Keefe  as Chief Customer and Strategy Officer

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE…

2 weeks ago
Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.

Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.

Funding supports pivotal Phase 3 trial for sovateltide, a potential first-in-class therapy that could transform the treatment of acute cerebral…

2 weeks ago
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era…

2 weeks ago
Cabaletta Bio Announces Proposed Public Offering of SecuritiesCabaletta Bio Announces Proposed Public Offering of Securities

Cabaletta Bio Announces Proposed Public Offering of Securities

PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company…

2 weeks ago
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 CongressCabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively…

2 weeks ago